PRESENTATION: Vildagliptin 50 mg /100 mg, Vildagliptin 50mg plus Metformin 500mg, Vildagliptin 50mg plus Metformin 1000mg

DRUG CLASS: DPP4 Inhibitor and Bigaunides

MECHANISM OF ACTION:  

Vildagliptin binds covalently to the catalytic site of DPP-4, eliciting prolonged enzyme inhibition. This raises intact GLP-1 levels, both after meal ingestion and in the fasting state. Vildagliptin has been shown to stimulate insulin secretion and inhibit glucagon secretion in a glucose-dependent manner

At hypoglycaemic levels, the counterregulatory glucagon response is enhanced relative to baseline by vildagliptin

Vildagliptin also inhibits hepatic glucose production, mainly through changes in islet hormone secretion, and improves insulin sensitivity

These effects underlie the improved glycaemia with low risk for hypoglycaemia.

 Vildagliptin also suppresses postprandial triglyceride (TG)-rich lipoprotein levels after ingestion of a fat-rich meal and reduces fasting lipolysis, suggesting inhibition of fat absorption and reduced TG stores in non-fat tissues.

Metformin decreases hepatic glucose production, decreasing intestinal absorption of glucose and improves insulin sensitivity (increases peripheral glucose uptake and utilization)

INDICATIONS & DOSAGE:  As Directed by the Physician